Holen Sie sich die Stockscreener-App
16.29
0.67%
-0.11
Schlusskurs vom Vortag:
$16.40
Offen:
$16.35
24-Stunden-Volumen:
99,916
Relative Volume:
1.06
Marktkapitalisierung:
$336.92M
Einnahmen:
$306.91M
Nettoeinkommen (Verlust:
$-59.11M
KGV:
-108.60
EPS:
-0.15
Netto-Cashflow:
$6.35M
1W Leistung:
-17.39%
1M Leistung:
-0.55%
6M Leistung:
+51.39%
1J Leistung:
+40.50%
1-Tages-Spanne:
$16.16
$17.00
1-Wochen-Bereich:
$16.16
$20.57
52-Wochen-Spanne:
$7.08
$20.90
Amarin Corp Adr Stock (AMRN) Company Profile
Firmenname
Amarin Corp Adr
Sektor
Telefon
353 1 6699 020
Adresse
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Vergleichen Sie AMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
16.29 | 341.00M | 306.91M | -59.11M | 6.35M | -0.15 |
|
LLY
Lilly Eli Co
|
862.86 | 757.06B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.87 | 455.48B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
218.04 | 403.13B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.79 | 235.26B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
85.98 | 215.51B | 63.43B | 16.42B | 14.72B | 6.4861 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-10-25 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-06 | Hochstufung | Jefferies | Hold → Buy |
| 2022-05-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-05-05 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-04 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-05-12 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-05 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-31 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-31 | Hochstufung | Oppenheimer | Underperform → Perform |
| 2020-03-13 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-02 | Eingeleitet | Cowen | Outperform |
| 2020-02-18 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-01-06 | Eingeleitet | JP Morgan | Neutral |
| 2019-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-20 | Eingeleitet | Oppenheimer | Underperform |
| 2019-11-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-11-15 | Bestätigt | SVB Leerink | Outperform |
| 2019-10-31 | Eingeleitet | Aegis Capital | Buy |
| 2019-10-15 | Eingeleitet | Goldman | Neutral |
| 2019-08-14 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-09 | Bestätigt | Jefferies | Buy |
| 2019-06-17 | Eingeleitet | ROTH Capital | Buy |
| 2019-03-22 | Eingeleitet | Stifel | Buy |
Alle ansehen
Amarin Corp Adr Aktie (AMRN) Neueste Nachrichten
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program - ADVFN
Cash from operating activities of Amarin Corporation Plc Sponsored ADR – SWB:EH3 - TradingView
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress - GlobeNewswire Inc.
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - Sahm
Amarin Corporation plc Announces $17.8 Million Registered Direct Offering of American Depositary Shares - ADVFN
Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable - Investing.com
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Amarin Gears Up To Report Q2 Earnings: Here's What To Expect - Barchart.com
VKTX Stock Down On Wider-Than-Expected Loss In Q2, Nil Sales - Barchart.com
Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin - Barchart.com
3 Strong Buy Breakout Stocks for Explosive Returns - The Globe and Mail
KRYS Begins Dosing With Gene Therapy In Rare Eye Disease, Stock Up - Barchart.com
RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com
PROK Surges More Than 500% On Upbeat Data From Kidney Cell Therapy Study - Barchart.com
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA - Sahm
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
KURA Stock Rises More Than 15% This Past Week: Here's Why - Barchart.com
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y - Barchart.com
Amarin earnings beat by $0.04, revenue topped estimates - Investing.com
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Barchart.com
Amarin Corp PLC Share Price ADR Each Rep 20 Ord Spon - Hargreaves Lansdown
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - markets.businessinsider.com
Amarin announces board member departure ahead of annual meeting - Investing.com
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
Amarin urged to review strategy by major shareholders - Investing.com
The Market Doesn't Like What It Sees From Amarin Corporation plc's (NASDAQ:AMRN) Revenues Yet As Shares Tumble 26% - Sahm
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Plans Major ADR Restructuring: What This 1:20 Ratio Change Means for Investors - Stock Titan
Amarin stock plunges to 52-week low of $0.46 amid challenges - Investing.com
Amarin granted extension to meet Nasdaq listing standards - Investing.com
Top 3 Health Care Stocks You'll Regret Missing In Q4Amarin Corp (NASDAQ:AMRN) - Benzinga
Amarin to present new cardiovascular research at ESC Congress - Investing.com
China approves VASCEPA to reduce cardiovascular risk - Investing.com
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Investing.com UK
Amarin's VAZKEPA gains reimbursement approval in Greece - Investing.com
Amarin secures new patent for heart drug VAZKEPA in Europe - Investing.com
Free float of Amarin Corporation Plc Sponsored ADR – NASDAQ:AMRN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Sarissa Capital Calls for Amarin Special Meeting to Vote on Its Nominees - 24/7 Wall St.
股神出手｜畢菲特首度買進台積電ADR 涉逾41.2億美元 4家避險基金均增持台積電 - Yahoo 財經
Amarin CorpADR (AMRN) News, Articles, Events & Latest Updates - Stocktwits
Validea Kenneth Fisher Strategy Daily Upgrade Report9/24/2022 - Nasdaq
AMRN Forecast — Price Target — Prediction for 2026 - TradingView
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics - Nasdaq
HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan - The Globe and Mail
Finanzdaten der Amarin Corp Adr-Aktie (AMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
1.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):